Skip to main content
Fig. 11 | Journal of Experimental & Clinical Cancer Research

Fig. 11

From: LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

Fig. 11

LCL161 increases paclitaxel-induced apoptosis by targeting cIAPs. Paclitaxel activates the TNFα pathway, leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex. LCL161 degrades cIAPs by increasing cIAP self-ubiquitination, which results in the release of RIP1, the formation of the caspase-8/RIP1/FADD complex, and the activation of caspase-8 and, ultimately, apoptosis

Back to article page